Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-(apurinic or apyrimidinic site) endonuclease 2 (APEX2) is an enzyme involved in the base excision repair (BER) pathway, a critical mechanism for repairing DNA lesions such as apurinic/apyrimidinic (AP) sites. APEX2 functions as a weak AP endodeoxyribonuclease, catalyzing the hydrolytic incision of the phosphodiester backbone at AP sites and initiating the repair process. While less active than the related enzyme APEX1, APEX2 contributes to genomic stability by processing DNA damage, particularly in response to oxidative stress. It is primarily localized intracellularly and interacts with proteins involved in DNA repair, including proliferating cell nuclear antigen (PCNA), and has a role in the regulation of repair complex recruitment and DNA repair synthesis. Impairment of APEX2 activity has been linked to increased sensitivity to DNA damage, and deficiencies may contribute to the pathology of cancer and other diseases related to defective DNA repair[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-(apurinic or apyrimidinic site) endonuclease 2 (APEX2).